Mein Warenkorb

Integrin alpha V beta 1

Integrin alpha V beta 1 Molekülinformation

Englischer NameIntegrin alpha-V/beta-1Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel5Target-Alias
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameIntegrin alpha-V/beta-1
Target-Alias
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel5
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Integrin alpha V beta 1 Molekülhintergrund

Integrin alpha V beta 1 (αVβ1) is a widely expressed adhesion receptor formed by the non-covalent association of the αV and β1 (CD29) subunits. Its activity is regulated by a conformational shift from a folded, low-affinity state to an extended, high-affinity state, a process triggered by divalent cations and intracellular signaling. As a canonical RGD-binding integrin, it interacts with ligands including vitronectin, fibronectin, and osteopontin. This interaction is central to its role in mediating cell migration, where its modest binding affinity enables the cyclic attachment and detachment necessary for cell movement. Furthermore, αVβ1 is implicated in cellular differentiation and is co-opted by pathogens, such as foot-and-mouth disease virus, for host cell entry.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
IDL-2965IDL-2965Phase 2 ClinicalIndalo Therapeutics IncIdiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
BexotegrastPLN-74809Phase 2 ClinicalPliant Therapeutics IncCholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult
Details
PLN-1474PLN-1474Phase 1 ClinicalPliant Therapeutics IncLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics IncSolid tumours
Details
Cu-64-LLP2ACu-64-LLP2A; 64Cu-LLP2APhase 1 ClinicalUniversity Of PittsburghAnemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns